ARS Pharmaceuticals, Inc. SEC filings SPRY
ARS Pharmaceuticals, Inc. has 549 filings in SEC EDGAR's recent list, going back to Apr 12, 2016. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 17, 2026 | Jul 15, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 7, 2026 | Jul 6, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 25, 2026 | Jun 24, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 15, 2026 | May 15, 2026 |
| 8-K |
Current report
Officer or director change
|
May 13, 2026 | May 12, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Mar 9, 2026 | Mar 9, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 10, 2025 | Nov 10, 2025 |
| 8-K |
Current report
Material agreement, New debt
|
Sep 29, 2025 | Sep 29, 2025 |
| 8-K |
Current report
Other events
|
Aug 28, 2025 | Aug 13, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 13, 2025 | Aug 13, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 26, 2025 | Jun 25, 2025 |
| 8-K |
Current report
Results of operations
|
May 14, 2025 | May 14, 2025 |
| 8-K |
Current report
Material agreement
|
May 2, 2025 | May 2, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 20, 2025 | Mar 20, 2025 |
| 8-K |
Current report
Other events
|
Mar 5, 2025 | Mar 5, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Jan 13, 2025 | Jan 13, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 13, 2024 | Nov 13, 2024 |
| 8-K |
Current report
Material agreement
|
Nov 12, 2024 | Nov 9, 2024 |
| 8-K |
Current report
Material agreement
|
Oct 15, 2024 | Oct 8, 2024 |
| 8-K |
Current report
Material agreement
|
Sep 23, 2024 | Sep 17, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Aug 12, 2024 | Aug 9, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2024 | Aug 6, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 28, 2024 | Jun 28, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 28, 2024 | Jun 27, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jun 21, 2024 | Jun 20, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
May 10, 2024 | May 10, 2024 |
| 8-K |
Current report
Results of operations
|
May 9, 2024 | May 9, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 21, 2024 | Mar 21, 2024 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Mar 7, 2024 | Mar 7, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 9, 2023 | Nov 9, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 25, 2023 | Sep 25, 2023 |
| 8-K |
Current report
Other events
|
Sep 20, 2023 | Sep 19, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2023 | Aug 10, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Jun 28, 2023 | Jun 27, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
May 16, 2023 | May 16, 2023 |
| 8-K |
Current report
Results of operations
|
May 15, 2023 | May 15, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
May 9, 2023 | May 9, 2023 |
| 8-K |
Current report
Results of operations
|
Mar 23, 2023 | Mar 23, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 13, 2023 | Mar 13, 2023 |
| 8-K |
Current report
Material agreement, Agreement ended
|
Feb 22, 2023 | Feb 22, 2023 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Feb 14, 2023 | Feb 14, 2023 |
| 8-K/A | Amended current report | Jan 17, 2023 | Nov 4, 2022 |
| 8-K |
Current report
Officer or director change
|
Dec 9, 2022 | Dec 6, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 6, 2022 | Dec 6, 2022 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Change in control, Officer or director change, Bylaw or fiscal year change, Shareholder vote results, Other events
|
Nov 8, 2022 | Nov 4, 2022 |
| 8-K |
Current report
Other events
|
Nov 2, 2022 | Nov 1, 2022 |
| 8-K |
Current report
Material agreement
|
Oct 27, 2022 | Oct 25, 2022 |
| 8-K |
Current report
Other events
|
Oct 21, 2022 | Oct 21, 2022 |
| 8-K |
Current report
Material agreement, Agreement ended
|
Sep 30, 2022 | Sep 27, 2022 |
| 8-K |
Current report
Officer or director change
|
Sep 2, 2022 | Sep 1, 2022 |
| 8-K |
Current report
Material agreement, Exit or restructuring costs, Officer or director change, Other events
|
Jul 21, 2022 | Jul 21, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Jun 13, 2022 | Jun 10, 2022 |
| 8-K |
Current report
Results of operations
|
May 12, 2022 | May 12, 2022 |
| 8-K |
Current report
Agreement ended
|
May 6, 2022 | May 2, 2022 |
| 8-K |
Current report
Results of operations
|
Mar 31, 2022 | Mar 31, 2022 |
| 8-K |
Current report
Officer or director change
|
Mar 17, 2022 | Mar 11, 2022 |
| 8-K |
Current report
Results of operations
|
Nov 10, 2021 | Nov 10, 2021 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 16, 2021 | Sep 16, 2021 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 13, 2021 | Sep 13, 2021 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2021 | Aug 12, 2021 |
| 8-K |
Current report
Material agreement, New debt
|
Jul 2, 2021 | Jul 1, 2021 |
| 8-K |
Current report
Shareholder vote results
|
Jun 9, 2021 | Jun 4, 2021 |
| 8-K |
Current report
Results of operations
|
May 13, 2021 | May 13, 2021 |
| 8-K |
Current report
Results of operations
|
Mar 29, 2021 | Mar 29, 2021 |
| 8-K |
Current report
Officer or director change
|
Mar 15, 2021 | Mar 12, 2021 |
| 8-K |
Current report
Bylaw or fiscal year change, Other events
|
Dec 8, 2020 | Dec 8, 2020 |
Showing 68 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SPRY (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1671858
- Former names
- Silverback Therapeutics, Inc. (until Nov 8, 2022)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.